Cargando…

Combination therapies for primary hepatic neuroendocrine carcinoma: a case report

BACKGROUND: Primary hepatic neuroendocrine carcinomas are extremely rare. Because of the rarity of PHNEC, its clinical features and treatment outcomes are not well understood. A proper diagnosis and the correct therapeutic approach therefore remain clinically challenging. CASE PRESENTATION: A 67-yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakatake, Richi, Ishizaki, Morihiko, Matui, Kosuke, Yanagimoto, Hiroaki, Inoue, Kentaro, Kaibori, Masaki, Kawaguchi, Yusai, Kon, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593802/
https://www.ncbi.nlm.nih.gov/pubmed/28895097
http://dx.doi.org/10.1186/s40792-017-0378-z
_version_ 1783263096504057856
author Nakatake, Richi
Ishizaki, Morihiko
Matui, Kosuke
Yanagimoto, Hiroaki
Inoue, Kentaro
Kaibori, Masaki
Kawaguchi, Yusai
Kon, Masanori
author_facet Nakatake, Richi
Ishizaki, Morihiko
Matui, Kosuke
Yanagimoto, Hiroaki
Inoue, Kentaro
Kaibori, Masaki
Kawaguchi, Yusai
Kon, Masanori
author_sort Nakatake, Richi
collection PubMed
description BACKGROUND: Primary hepatic neuroendocrine carcinomas are extremely rare. Because of the rarity of PHNEC, its clinical features and treatment outcomes are not well understood. A proper diagnosis and the correct therapeutic approach therefore remain clinically challenging. CASE PRESENTATION: A 67-year-old man was admitted to our department because of a liver tumor. Computed tomography revealed a single liver tumor 50 mm in diameter and located in the S3 region. Biopsy and imaging findings resulted in a diagnosis of primary hepatic neuroendocrine carcinoma. Left lateral segmentectomy was performed. Immunohistochemically, the tumor cells were positive for synaptophysin, chromogranin A, and CD56. Ki-67 was positive in > 90% of the tumor cells. The final diagnosis was primary hepatic neuroendocrine carcinoma. The patient suffered two episodes of lymph node recurrence. Nonetheless, the tumor was excised to prolong survival. Thus, after lymphadenectomy, he received adjuvant chemotherapy for 6 months. Two years after surgery, the patient remains alive and in good general condition. CONCLUSIONS: In most cases, primary hepatic neuroendocrine carcinoma, while extremely rare, has a poor prognosis. At present, surgical resection is a priority for curative treatment, but in patients with recurrence, combined therapies are recommended.
format Online
Article
Text
id pubmed-5593802
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-55938022017-09-27 Combination therapies for primary hepatic neuroendocrine carcinoma: a case report Nakatake, Richi Ishizaki, Morihiko Matui, Kosuke Yanagimoto, Hiroaki Inoue, Kentaro Kaibori, Masaki Kawaguchi, Yusai Kon, Masanori Surg Case Rep Case Report BACKGROUND: Primary hepatic neuroendocrine carcinomas are extremely rare. Because of the rarity of PHNEC, its clinical features and treatment outcomes are not well understood. A proper diagnosis and the correct therapeutic approach therefore remain clinically challenging. CASE PRESENTATION: A 67-year-old man was admitted to our department because of a liver tumor. Computed tomography revealed a single liver tumor 50 mm in diameter and located in the S3 region. Biopsy and imaging findings resulted in a diagnosis of primary hepatic neuroendocrine carcinoma. Left lateral segmentectomy was performed. Immunohistochemically, the tumor cells were positive for synaptophysin, chromogranin A, and CD56. Ki-67 was positive in > 90% of the tumor cells. The final diagnosis was primary hepatic neuroendocrine carcinoma. The patient suffered two episodes of lymph node recurrence. Nonetheless, the tumor was excised to prolong survival. Thus, after lymphadenectomy, he received adjuvant chemotherapy for 6 months. Two years after surgery, the patient remains alive and in good general condition. CONCLUSIONS: In most cases, primary hepatic neuroendocrine carcinoma, while extremely rare, has a poor prognosis. At present, surgical resection is a priority for curative treatment, but in patients with recurrence, combined therapies are recommended. Springer Berlin Heidelberg 2017-09-11 /pmc/articles/PMC5593802/ /pubmed/28895097 http://dx.doi.org/10.1186/s40792-017-0378-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Case Report
Nakatake, Richi
Ishizaki, Morihiko
Matui, Kosuke
Yanagimoto, Hiroaki
Inoue, Kentaro
Kaibori, Masaki
Kawaguchi, Yusai
Kon, Masanori
Combination therapies for primary hepatic neuroendocrine carcinoma: a case report
title Combination therapies for primary hepatic neuroendocrine carcinoma: a case report
title_full Combination therapies for primary hepatic neuroendocrine carcinoma: a case report
title_fullStr Combination therapies for primary hepatic neuroendocrine carcinoma: a case report
title_full_unstemmed Combination therapies for primary hepatic neuroendocrine carcinoma: a case report
title_short Combination therapies for primary hepatic neuroendocrine carcinoma: a case report
title_sort combination therapies for primary hepatic neuroendocrine carcinoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593802/
https://www.ncbi.nlm.nih.gov/pubmed/28895097
http://dx.doi.org/10.1186/s40792-017-0378-z
work_keys_str_mv AT nakatakerichi combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport
AT ishizakimorihiko combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport
AT matuikosuke combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport
AT yanagimotohiroaki combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport
AT inouekentaro combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport
AT kaiborimasaki combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport
AT kawaguchiyusai combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport
AT konmasanori combinationtherapiesforprimaryhepaticneuroendocrinecarcinomaacasereport